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HIV, London School of Hygiene and Tropical Medicine, London, UK
ABSTRACT
Objective: We aimed to observe (i) changes in fasting blood glucose (FBG) in tuberculosis (TB)
patients before and during anti-TB treatment, (ii) whether FBG levels were stable or unstable
and (iii) baseline characteristics associated with an unstable FBG.
Method: TB patients consecutively attended six clinics or hospitals. FBG measurements were
made at months 0, 2 and 6. Data analysis was performed using the chi-square test and
multivariate logistic regression.
Results: Of 232 patients without diabetes mellitus (DM) whose initial FBG < 6.1 mmol/L, over
90% maintained FBG < 6.1 mmol/L during treatment and no patient developed DM. Of 17
patients without DM and initial FBG between 6.1 and 6.9 mmol/L, over half had FBG <
6.1 mmol/L during treatment and no patient had DM at the end of treatment. Eight DM
patients with already known DM had their FBG controlled at < 7.0 mmol/L during treatment.
There were 13 DM patients newly diagnosed with FBG ≥ 7.0 mmol/L, and 69% continued to
have FBG ≥ 7.0 mmol/L. After adjustment for confounding, the odds for an unstable FBG were
higher for HIV-positive status, already having DM, smoking and coming to hospitals rather
than clinics.
Conclusion: TB patients who do not have DM based on FBG measurements do not develop
DM during anti-TB treatment. Those newly diagnosed with DM on screening in general
maintain their DM status with high FBG and need to be better managed.
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Background
Despite efforts for the last 25 years from the global
community to control tuberculosis (TB), the dis-
ease remains a major global public health threat. In
2014, an estimated 9.6 million people developed
active TB and 1.5 million people were estimated
to have died from the disease [1]. In the last dec-
ade, the world has also witnessed an escalating
epidemic of diabetes mellitus (DM) which has
arisen as a consequence of population growth,
aging, urbanization and lifestyle changes. Available
data suggest that an estimated 415 million people
worldwide live with DM and another 318 million
people have impaired glucose tolerance, which if
left unchecked can progress to DM. By 2040 these
numbers are predicted to grow to 642 million and
481 million, respectively [2].
People with DM have a significantly higher risk of
developing active TB which is 2–3 times higher than
in those with no diabetes [3]. DM patients with TB
are also reported to have worse treatment outcomes
compared with patients without DM, with delays in
sputum culture conversion, an increased risk of fail-
ure or death during anti-TB treatment and an
increased risk of recurrent disease after successful
completion of anti-TB treatment [4–6].
To address this progressively worsening health pro-
blem in low- and middle-income countries and the
linkage between the two diseases, the World Health
Organization (WHO) and the International Union
Against Tuberculosis and Lung Disease (the Union)
launched a ‘Collaborative Framework for Care and
Control of Diabetes and Tuberculosis’ in 2011, with
one of the important recommendations being the
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implementation of bi-directional screening of the two
diseases within the routine health services [7].
In the meantime, The Union, together with
national authorities, implemented the first bi-direc-
tional screening of DM and TB in 6 TB clinics and 5
DM clinics within the routine health services across
China. Bi-directional screening was found to be fea-
sible with two published studies describing the imple-
mentation, the results and the challenges of screening
DM and TB within routine health care settings [8,9].
During the screening of TB patients for DM, one
of the important issues with the process, which is
undertaken soon after TB registration and at the
start of anti-TB treatment, is that TB may induce
infection-related hyperglycaemia [9–11]. A small-
scale study in Nigeria, assessing blood glucose toler-
ance at multiple points during the course of anti-TB
treatment, also reported that the prevalence of abnor-
mal results decreased over time [12], leading to the
questions of when is the best time to take blood
glucose measurements and whether one blood test is
enough to diagnose or rule out DM for the majority
of TB patients. To help answer these questions, we
conducted an observational cohort study to under-
stand if blood glucose levels were stable or fluctuated
during the course of anti-TB treatment in multiple
settings in different provinces of China. This paper
reports the findings from this study.
Methods
Design
This was a prospective cohort observational study
carried out at six TB clinics and hospitals within
routine health services in three provinces of China.
The total sample size was calculated using a 2-sided
significance level of 0.05 and a power of 0.8. We
assumed that 8% of TB patients at TB clinics would
have unstable FBG, but the proportion of TB patients
with unstable FBG at hospital was in fact 20%.
Therefore, the minimum required sample size was
221. Taking into account a loss to follow-up of
about 20% or patients not presenting within
±7 days at the end of month 2 or the end of month
6 of anti-TB treatment, we needed to recruit at least
266 TB patients.
Setting and sites
The experience of screening TB patients for DM in
2011–2012 led to a decision that the study should be
carried out in settings where different types of TB
patient could be included. Therefore, four TB clinics
and two TB hospitals across mainland China were
selected. These were: Changchun Communicable
Disease Hospital, Jilin City TB Institute, Shuang
Yang District TB Institute, Ganzhou No. 5 Hospital,
Beijing TB Institute and Yudu County TB Institute.
Selection of the clinics and hospitals was based on
broad geographical coverage, a sufficient number of
TB patients stratified by different types of disease
who had been registered 1 year previously, availability
of TB and DM diagnostic and treatment facilities and
willingness of the staff to participate in this study.
Patients
All patients who were consecutively diagnosed and
registered with TB from February to July 2015 were
included in the study.
Anti-TB treatment
All TB patients were registered, treated and managed
according to the guidelines of the China National TB
Control Program [13]. Treatment regimens and anti-
TB drug formulations were administered in accordance
with those recommended by WHO and in line with
National Tuberculosis Program (NTP) guidelines [14].
The standardized treatment regimen consists of
2 months of thrice-weekly isoniazid, rifampicin, pyra-
zinamide and ethambutol followed by 4 months of
thrice-weekly isoniazid and rifampicin.
Blood sugar measurement for TB patients
Blood samples were collected for FBG in all patients
after an overnight fast of at least 10 hours. FBG
measurements were in line with national guidelines
which stipulate that a FBG measurement is carried
out using venous plasma and a biochemical analyzer
with cut-off thresholds based on those recommended
by the WHO [15]. In brief, a fasting blood glucose
(FBG) ≥ 7.0 mmol/L (126 mg/dl) indicates DM; a
FBG of 6.1–6.9 mmol/L (110 mg/dl to less than
126 mg/dl) indicates impaired glucose tolerance; a
FBG < 6.1 mmol/L (110 mg /dl) is normal. For
every newly diagnosed and registered TB patient, we
took the first blood sample for FBG immediately after
the TB diagnosis; and this was followed by FBGs
within ±7 days of the end of month 2 and the end
of month 6 of anti-TB treatment, respectively. For
any patient who was not fasting at the first visit, an
additional visit was scheduled for FBG to be per-
formed on the following day.
Data collection and recording
A standardized questionnaire was developed for data
collection focusing on demographic characteristics,
types of TB, symptoms, complications and cigarette
smoking status. Patients were diagnosed with DM
either as a result of this being known (diagnosed at
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any time by a registered medical institution and
documented in the clinic notes) or as a result of
FBG ≥ 7.0 mmol/L being found at the time of TB
registration or at the time of TB diagnosis from
another health facility. The results of the FBG mea-
surements at the different time periods were also
recorded in the same questionnaire. The question-
naire was compiled by TB clinic staff and reviewed
by Union staff during the monitoring visit and before
data analysis.
Quality assurance
Blood sample
Blood samples for FBG at the six TB clinics/hospitals
were all from venous plasma: no capillary blood tests
were done.
Biochemical analyser
The type of biochemical analyser used at the four TB
clinics was Mairui BS-300, BS-320 or BS-350, pro-
duced in Shenzhen, China; the analyser type at the
two hospitals was a Hitachi-7100. National Reference
Laboratory staff ensured that the different biochem-
ical analysers gave consistent and accurate results
through external quality assurance.
Field monitoring
Supervision and site visits were carried out by staff of
the Union and provincial TB staff during the period
of the study.
Data analysis and statistics
Individual patient data were received and cross-
checked by staff of the Union and provincial TB
staff, and were then double-entered into an Excel
file and analysed. TB patients were categorized into
having stable FBG (defined as a variation between
baseline FBG and month 2 and/or month 6 FBG of
≤ 1.0 mmol/L) or unstable FBG (defined as a varia-
tion between baseline FBG and month 2 and/or
month 6 FBG of > 1.0 mmol/L). Comparisons of
baseline characteristics between TB patients with
stable or unstable FBG were carried out using the
chi-square test with odds ratios (O.Rs) and their
95% confidence intervals. Levels of significance were
set at 5%. We selected variables with unadjusted O.Rs
for which the P-value was < 0.2 and included these in
the multivariate logistic regression model.
Results
There were 303 TB patients consecutively registered
in this study. Of these, 15 were lost and 18 missed the
accepted timing of FBG which should have been done
within ±7 days of the end of month 2 or the end of
month 6 of anti-TB treatment. Therefore 270 TB
patients were eligible for this study. This included
68 with smear-positive pulmonary TB, 187 with
smear-negative pulmonary TB and 15 with extra pul-
monary TB (EPTB). There were 179 males and 91
females, aged from 10 years to 88 years old with an
average age of 42.1 years. Of the 270 TB patients, 21
had DM (8 were already known to have DM and 13
were newly diagnosed as having DM) and 249 had no
DM. The distribution of FBG levels for those without
DM was as follows: 232 persons had their FBG <
6.1 mmol/L and 17 persons had their FBG between
6.1 and 6.9 mmol/L; no person had FBG ≥ 7.0 mmol/
L. Of the 21 patients with DM, the FBG level at the
time of registration was as follows: 5 persons had
their FBG < 6.1 mmol/L, 3 persons had their FBG
between 6.1 and 6.9 mmol/L and 13 had their FBG ≥
7.0 mmol/L.
Table 1(A–D) shows the number of TB patients
with different FBG levels at month 2 and month 6,
stratified by those without DM and those with DM.
For those without DMwhose initial FBG < 6.1 mmol/L
(Table 1A), over 90% had their FBG < 6.1 mmol/L in
month 2 and month 6, with 4.7% and 7.3% moving up
into the FBG range of 6.1–6.9 mmol/L in month 2 and
month 6, respectively. Of the 17 patients without DM
whose initial FBG was between 6.1 and 6.9 mmol/L
(Table 1B), over half moved to an FBG < 6.1 mmol/L
in months 2 and 6. Three of the patients moved to FBG
≥ 7.0 mmol/L at month 2, but all moved down in
month 6. For the eight patients with already known
DM, blood glucose levels varied at month 2 or 6 with
over half of the patients at each time period having
FBG < 7.0 mmol/L (Table 1C). For the 13 patients with
newly diagnosed DM and FBG ≥ 7.0 mmol/L at month
0 (Table 1D), most continued to have FBG ≥
7.0 mmol/L with only one patient (the same patient)
having a normal FBG at month 2 and month 6,
respectively.
Baseline characteristics of TB patients in relation
to having an unstable FBG at month 2 and month 6
during anti-TB treatment are shown in Table 2. Odds
on univariate analysis of a patient having an unstable
FBG were caused by being HIV-positive, already
known to have DM or newly diagnosed with DM,
smoking cigarettes and coming to a hospital rather
than to a clinic. After adjusting for possible con-
founding factors, odds of association with an unstable
FBG were caused by being HIV positive, having DM,
smoking cigarettes and those who presented to a
hospital rather than a clinic.
The trends in blood glucose levels during anti-TB
treatment were assessed in those without DM in
relation to baseline characteristics. There were no
significant trends observed apart from HIV status
(Figure 1): P = 0.164 for patients with fever and
without fever, P = 0.133 for those with haemoptysis
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and without haemoptysis, P = 0.319 for those with
liver disease and without liver disease, P = 0.399 for
different type of TB, and P = 0.048 among HIV-
positive, HIV-negative and HIV not-tested.
Discussion
To our knowledge, this is the first study inChina to assess
changes in blood glucose levels in TB patients throughout
anti-TB treatment. We conducted the study within the
routine health services including both public health TB
clinics and hospitals to ensure recruitment of patients
with different types of TB. All patients were consecutively
enrolled in the study to avoid selection bias.
The overall prevalence of DM in the recruited TB
patients was 7.8%. This was lower than that observed
previously when screening was done in urban areas
[9], but similar to what has been observed from rural
Table 1. Fasting blood glucose levels at month 2 and month 6 in TB patients, stratified by those without DM and those already
diagnosed or newly diagnosed with DM.
Month 0 Month 2 Month 6
A: Fasting blood glucose levels at month 2 and month 6 in TB patients without DM whose fasting blood glucose < 6.1 mmol/L at the time of registration
No. TB patients with FBG < 6.1 mmol/L 232 (100) 221 (95.3) 215 (92.7)
No. TB patients with FBG 6.1–6.9 mmol/L _ 11 (4.7) 17 (7.3)
No. TB patients with FBG ≥ 7.0 mmol/L _ 0 (0) 0 (0)
Total 232 (100) 232 (100) 232 (100)
B: Fasting blood glucose levels at month 2 and month 6 in TB patients without DM whose fasting blood glucose was 6.1–6.9 mmol/L at the time of registration
No. TB patients with FBG < 6.1 mmol/L _ 9 (52.9) 10 (58.8)
No. TB patients with FBG 6.1–6.9 mmol/L 17 (100) 5 (29.4) 7 (41.2)
No. TB patients with FBG ≥ 7.0 mmol/L _ 3 (17.7) 0 (0)
Total 17 (100) 17 (100) 17 (100)
C: Fasting blood glucose levels at month 2 and month 6 in TB patients with already diagnosed DM whose fasting blood glucose was < 7.0 mmol/L at the time of registration
No. TB patients with FBG < 7.0 mmol/L 8 (100) 4 (50.0) 3 (37.5)
No. TB patients with FBG 6.1–6.9 mmol/L _ 1 (12.5) 3 (37.5)
No. TB patients with FBG ≥ 7.0 mmol/L _ 3 (37.5) 2 (25.0)
Total 8 (100) 8 (100) 8 (100)
D: Fasting blood glucose levels at month 2 and month 6 in TB patients with newly diagnosed DM whose fasting blood glucose was ≥ 7.0 mmol/L at the time of registration
No. TB patients with FBG < 6.1 mmol/L _ 1 (7.7) 1 (7.7)
No. TB patients with FBG 6.1–6.9 mmol/L _ 1 (7.7) 3 (23.0)
No. TB patients with FBG ≥ 7.0 mmol/L 13 (100) 11 (84.6) 9 (69.3)
Total 13 (100) 13 (100) 13 (100)
Notes: TB = tuberculosis; DM = diabetes mellitus; FBG = fasting blood glucose. Data are presented as n (%).
Table 2. Baseline characteristics in TB patients in relation to unstable fasting blood glucose levels during the 6-month course of
anti-TB treatment.
Characteristics
Total
N = 270
No. (%) with unstable FBG
(N = 80) Univariate OR (95% CI)
Multivariate adjusted
OR (95% CI) P-value
Total 270 80 (29.6)
Sex Female 91 21 (23.1) Reference
Male 179 59 (33.0) 1.639 (0.919–2.923)
Age < 20 22 5 (22.7) Reference
20–59 187 47 (25.1) 1.141 (0.399–3.263)
≥ 60 61 28 (45.9) 4.210 (0.944–8.816)
TB
Type
Smear – 187 54 (28.9) Reference
Smear + 68 21 (31.9) 1.100 (0.602–2.013)
EPTB 15 5 (33.3) 1.231 (0.402–3.771)
Fever No 183 48 (26.2) Reference
Yes 87 32 (36.8) 1.636 (0.948–2.820)
Haemoptysis No 246 71 (28.9) Reference
Yes 24 9 (37.5) 1.479 (0.619–3.534)
HIV status Negative 142 49 (34.5) Reference
Positive 9 6 (66.7) 3.796 (0.910–15.837) 6.668 (1.245–35.706) 0.027
Not-tested 119 25 (21.0) 0.505 (0.288–0.884) 0.640 (0.308–1.332) 0.233
Diabetes No 249 62 (24.9) Reference
Yes 21 18 (85.7) 18.097 (5.156–63.515) 17.016 (4.669–62.014) < 0.0001
Liver diseases No 256 74 (28.9) Reference
Yes 14 6 (42.9) 1.845 (0.619–5.500)
Smoking
cigarettes/day
0 186 47 (25.3) Reference
1–19 66 29 (43.9) 2.318 (1.288–4.173) 2.660 (1.374–5.150) 0.004
≥ 20 10 4 (40.0) 1.972 (0.533–7.290) 3.010 (0.623–14.551) 0.170
Not 8 0 (0)
clear
Source of patients TB clinic 163 32 (19.6) Reference
TB hospital 107 48 (44.9) 3.331 (1.396–5.731) 2.422 (1.209–4.852) 0.013
Notes: TB = tuberculosis; DM = diabetes mellitus; FBG = fasting blood glucose; CI: confidence intervals; smear + = smear-positive pulmonary TB; smear
– = smear-negative pulmonary TB; EPTB = extra-pulmonary TB.
An unstable FBG was defined as a change in fasting blood glucose of more than 1.0 mmol/L between baseline and 2 months or 6 months during the 6-
month anti-TB treatment.
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China [16]. However, it is important to note that the
use of FBG alone to diagnose DM can underestimate
the prevalence of this disease by as much as 50%
when compared with gold standard testing using the
cumbersome but more accurate oral glucose tolerance
test [17]. We therefore believe that the actual preva-
lence of DM among our TB patients might be higher
than what we have observed.
While more than half of the TB patients with
already known DM had FBG less than 7.0 mmol/L
during anti-TB treatment and were therefore well
controlled, this was not the case with those newly
diagnosed during the screening process with a high
proportion continuing to have FBG at or higher than
7.0 mmol/L. This is not acceptable. Previous studies
have shown that enhanced DM case management and
improved blood glucose control can lead to improved
TB treatment outcomes [5,18,19], and in future, DM
care and high-quality treatment need to improve for
our patients in order to optimize treatment outcomes.
It was reassuring that the large majority of TB
patients who started anti-TB treatment with a normal
FBG maintained a normal FBG or demonstrated
some impaired glucose tolerance yet no patient devel-
oped DM. Similarly, of the three patients who had
impaired glucose tolerance at baseline and then
developed a high FBG ≥ 7.0 mmol/L at 2 months,
none maintained this abnormally high FBG or devel-
oped DM by the end of treatment. This suggests that,
in resource-constrained environments, a patient with
FBG < 7.0 mmol/L at baseline need not be closely
followed up. As early detection and treatment for DM
can improve treatment outcomes for TB [7,11,18],
this finding also suggests that taking one blood sam-
ple for FBG immediately after TB diagnosis would be
appropriate for the majority of TB patients. These
results are similar to a study on 54 Nigerian TB
patients followed during treatment, which reported
that nearly half had initial abnormal glucose tolerance
with most reverting back to normal within 3 months
of anti-TB treatment; this study suggested that glu-
cose intolerance in pulmonary TB patients is second-
ary to infection and is reversible [12,19,20].
Our results in patients with impaired glucose
tolerance are also similar to what has been found
elsewhere [12,19–21]. Impaired glucose tolerance is
an indicator for future high risk of DM, and while
none of our patients in this study went on to
develop DM, lifestyle counselling, health promotion
and follow-up should be given to prevent or delay
the onset of DM [22]. Given that patients with TB
anyway are, or should be, counselled about healthy
diet, avoidance of smoking, harmful use of alcohol
and increasing outdoor physical activity, linking this
advice at no or marginal additional cost would be
beneficial as an overall public health strategy to
prevent DM.
An intriguing finding that requires further study
was that patients with smear-positive TB or with
haemoptysis, features that tend to reflect more
severe disease, were not at increased risk of having
unstable blood glucose levels during anti-TB treat-
ment. This goes against the traditional assumption
and the preliminary finding of the Nigerian study
that patients with more advanced or extensive dis-
ease may be more likely to have increased stress and
therefore more unstable blood glucose levels during
treatment.
Certain characteristics were associated with
unstable blood glucose levels. Although there were
only small numbers of patients with HIV-associated
TB, the diagnosis of HIV was a strong risk factor.
Both HIV and TB can damage the immune system
and this might result in poor glycaemia regulation
[23]. However, apart from noting the association, we
are unable to comment further or offer any useful
speculation about the reason as we have no informa-
tion about stage of HIV-disease, CD4 cell counts or
whether the patients were on antiretroviral therapy.
One unexpected finding that requires further study
was that trends in blood glucose levels against the
baseline value were significantly different among
those HIV-positive, HIV-negative and HIV not-
tested as shown in Figure 1. The reasons are spec-
ulative, but both HIV infection itself and antiretro-
viral drugs have metabolic effects which may play a
part. Cigarette smoking was an important risk factor
and this has not been reported in previous studies.
This association requires further research with possi-
ble reasons including the link between smoking and
venous thromboembolism and pancreatic damage
which may lead to impaired production of insulin
and glycaemia regulation [24,25]. It is unclear why
the association between unstable FBG and heavy
smoking (smoke ≥ 20 cigarettes/day) is weak and
Figure 1. Trends of blood sugar change in TB patients who
were HIV-positive, HIV-negative and HIV not-tested.
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this may in fact be due to a small number of cases. TB
patients with DM, perhaps not surprisingly, had a
much higher risk compared with TB patients without
DM, suggesting that more attention needs to be paid
to ensuring better DM control during treatment.
Finally, TB patients presenting to TB hospitals also
had a higher risk of unstable blood glucose compared
with those presenting to TB clinics, and on discussing
these findings with health workers this may be
because those coming to hospital have more severe
disease than those coming to clinics.
Our study has several limitations. We took three
blood samples during the entire course of anti-TB
treatment and therefore do not know how the FBG
measurements change within and beyond month 6. In
addition, blood glucose was only measured by FBG
and not by glycosylated haemoglobin (HbA1C), which
does indeed provide an index of blood glucose levels
over a period of 2–3 months and is not subject to the
rapid swings that can occur with FBG measurements
[26]. Although only small numbers of patients with
already known DM were identified, we do not know
exactly what drugs were used or how they were used
and thus are not able to comment on these effects on
blood glucose levels. We also did not collect any infor-
mation on other potentially important characteristics
such as whether patients delayed accessing health ser-
vice care or whether they adhered to treatment.
Conclusion
This study shows that patients with TB who do not
have DM on FBG measurement, including those with
impaired glucose tolerance, do not develop DM dur-
ing anti-TB treatment. However, those who are found
to have newly diagnosed DM on screening in general
maintain their DM status with high FBG and need to
be better managed. Certain baseline characteristics
such as HIV-positivity and smoking are associated
with unstable blood glucose levels during anti-TB
treatment and these patients need closer attention.
Useful programmatic lessons can be learnt from the
findings.
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Paper context
Tuberculosis patients should be screened for diabetes.
However, what is the best time to take blood glucose
measurements and whether one blood test is enough as
tuberculosis may induce infection-related hyperglycaemia?
To help answer this question, this paper reports finding
from an observational cohort study to understand if blood
glucose levels were stable or fluctuated during the course of
anti-TB treatment in multiple settings in different pro-
vinces of China.
References
[1] World Health Organization. WHO report 2015.
Global Tuberculosis Control 2015. [cited 2015
September] Available from: www.who.int/tb/publica
tion/global_report/en
[2] International Diabetes Federation. IDF diabetes atlas.
7th ed. Brussels: International Diabetes Federation;
2015. Available from: http://www.eatlas.idf.org
[3] Kapur A, Harries AD. The double burden of diabetes
and tuberculosis-public health implications. Diabetes
Res Clin Pract. 2013;101:10–19.
[4] Ruslami R, Aarnoutse RE, Alisjahbana B, et al.
Implications of the global increase of diabetes for
tuberculosis control and patient care. Trop Med Int
Health. 2010;15:1289–1299.
[5] Baker MA, Harries AD, Jeon CY, et al. The impact of
diabetes on tuberculosis treatment outcomes: a sys-
tematic review. BMC Med. 2011;9:81.
[6] Wang Q, Ma A, Han X, et al. Hyperglyceamia is
associated with increased risk of patient delay in pul-
monary tuberculosis in rural areas. J Diabetes. 2016
Aug 10. DOI:10.1111/17530407.12459
[7] The International Union Against Tuberculosis and
Lung Disease and World Health Organization.
Collaborative framework for care and control of
tuberculosis and diabetes. Geneva: WHO; 2011.
WHO/HTM/TB/2011.15.
[8] Lin Y, Li L, Mi FL, et al. Screening of patients with
diabetes mellitus for tuberculosis in China. Trop Med
Int Health. 2012;17:1302–1308.
6 Y. LIN ET AL.
D
ow
nl
oa
de
d 
by
 [L
on
do
n S
ch
oo
l o
f H
yg
ien
e &
 T
ro
p M
ed
ici
ne
] a
t 0
6:5
6 1
0 A
ug
us
t 2
01
7 
[9] Li L, Lin Y, Mi F, et al. Screening of patients with
tuberculosis for diabetes mellitus. Trop Med Int
Health. 2012;17:1294–1301.
[10] Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes
and tuberculosis: the impact of the diabetes epidemic
on tuberculosis incidence. BMC Public Health.
2007;7:234.
[11] Harries AD, Kumar AMV, Satyanarayana S, et al.
Diabetes mellitus and tuberculosis: programmatic
management issues. Int J Tuberc Lung Dis.
2015;19:879–886. DOI:10.5588/ijtld.15.0069
[12] Oluboyo PO, Erasmus RT. The significance of glucose
intolerance in pulmonary tuberculosis. Tubercle.
1990;71:135–138.
[13] Ministry of Health and China CDC. Guideline of
national TB control program. Beijing: The Peking
Union Medical College Publishing House; 2008.
[14] World Health Organization. Treatment of tuberculo-
sis guidelines. 4th ed. Geneva (Switzerland): WHO;
2009. WHO/HTM/TB/2009.420.
[15] World Health Organization and International
Diabetes Federation. Definition and diagnosis of dia-
betes mellitus and intermediate hyperglycaemia.
Geneva (Switzerland): WHO; 2006. Available from:
www.who.int/diabetes/publications/diagnosis_dia
betes2006/en/
[16] Wang Q, Han X, Ma A, et al. Screening and interven-
tion of diabetes in patients with pulmonary tubercu-
losis in poverty zones in China: rational and study
design. Diabetes Res Clin Pract. 2012;96:385–391.
[17] Mugusi F, Swai AB, Alberti KG, et al. Increased pre-
valence of diabetes mellitus in patients with pulmonary
tuberculosis in Tanzania. Tubercle. 1990;71:271–276.
[18] Lo H-Y, Yang S-L, Lin H-H, et al. Does enhanced
diabetes management reduce the risk and improve
the outcome of tuberculosis? Int J Tuberc Lung Dis.
2016;20:376–382.
[19] Singh MM, Biswas SK, Shah A, et al. Impaired glucose
tolerance in active pulmonary tuberculosis. Indian J
Tuberc. 1984;31:118–121.
[20] Kishore B, Nagrath SP, Mathur KS, et al. Manifest,
chemical and latent chemical diabetes in pulmonary
tuberculosis. J Assoc Physicians India. 1973;21:875–
881.
[21] Goyal BN, Nigam P, Dubey AL, et al. Study of the
diabetic status in pulmonary tuberculosis. J Diabetes
Assoc India. 1978;18:191–197.
[22] Perreault L, Pan Q, Mather KJ, et al. Effect of regres-
sion from prediabetes to normal glucose regulation on
long-term reduction in diabetes risk: results from the
diabetes prevention program outcomes study. Lancet.
2012;379:2243–2251.
[23] Harries AD, Lin Y, Satyanarayana S, et al. The loom-
ing epidemic of diabetes-associated tuberculosis:
learning lessons from HIV-associated tuberculosis.
Int J Tuberc Lung Dis. 2011;15:1436–1444.
[24] Shefey O, Eriksen M, Ross H, et al. The tobacco atlas.
3rd ed. American Cancer Society and World Lung
Founda t i on ; 2009 . Ava i l a b l e f rom : www .
TobaccoAtlas.org
[25] World Health Organization. WHO report on the glo-
bal tobacco epidemic 2008 (the MPOWER package).
Geneva (Switzerland); 2008. Available from: WHO/
tobacco/mpower/WM/290
[26] World Health Organization. 2011. Use of glycated
haemoglobin (HbA1c) in the diagnosis of diabetes
mellitus: abbreviated report of a WHO consultation.
Geneva (Switzerland): WHO. [cited 2011 Sep 14].
Available from: http://www.who.int/cardiovascular_
diseases/report-hba1c_2011_edited.pdf
GLOBAL HEALTH ACTION 7
D
ow
nl
oa
de
d 
by
 [L
on
do
n S
ch
oo
l o
f H
yg
ien
e &
 T
ro
p M
ed
ici
ne
] a
t 0
6:5
6 1
0 A
ug
us
t 2
01
7 
